Author:
Batra Ullas,Nathany Shrinidhi
Subject
Cancer Research,Oncology (nursing),Drug Guides,Ophthalmology
Reference76 articles.
1. NCCN guidelines insights: Non-small cell lung cancer, version 2.2021;Ettinger;J Natl Compr Canc Netw,2021
2. MET copy number as a secondary driver of epidermal growth factor receptor tyrosine kinase inhibitor resistance in EGFR-mutant non–small-cell lung cancer;Camidge;J Clin Oncol,2019
3. Suzawa K, Offin M, Schoenfeld AJ, Plodkowski AJ, Odintsov I, Lu D, et al. Acquired MET exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer. JCO Precis Oncol 2019;3:PO.19.00011.
4. Resistance mechanisms to epidermal growth factor receptor inhibitors in non-small cell lung cancer;Bondili;Cancer Res Stat Treat,2020
5. Treatment of advanced non-small-cell lung cancer: First line, maintenance, and second line – Indian consensus statement update (Under the aegis of Lung Cancer Consortium Asia, Indian Cooperative Oncology Network, Indian Society of Medical and Pediatric Oncology, Molecular Oncology Society, and Association of Physicians of India);Prabhash;Cancer Res Stat Treat,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献